Pharmacology Flashcards
Half life of mifepristone
25-30hours
Structure of heparin
Polysaccharide (repeating disaccarides)
Amount of hormone released in LNG in 24 hours (mirena)
20 micrograms/ 24 hours
MOA Fluconazole
Inhibits synthesis of ergosterol from lanosterol, inhibiting cell wall synthesis
MOA labetalol
Competitive alpha-1 (selective) and non-selective beta-1 blocker (antagonist)
MOA warfarin
Competitively inhibits vit K epoxide reductase complex 1. Interferes with synthesis of vitamin K dependent clotting factors (X, IX, VII and II- 1972)
MOA dalteparin
Factor Xa and thrombin inhibitor
MOA raltegavir
Integrase inhibitor
Metabolism of isoniazid
N-acetylation of its hydrazine in the liver
MOA of methotrexate
Dihydrofolate reductase inhibitor
MOA of clomiphene citrate
When should it be taken? Dose?
Selective estrogen receptor modulator:
Induces LH/FSH release by occupying oestrogen receptors in hypothalamus, promoting FSH release.
Stimulates ovarian aromatase activity and up regulate of granulosa LH receptors.
Stimulates ovulation
D2-6 of cycle. 50-100mg.
Dinoprostone MOA
Prostaglandin E2- stimulates uterine contractions
Contraceptive implant MOA
Ovulation inhibition and increase in viscosity of cervical mucus.
Teratogenic effect of ACEi
Fetal renal damage
Oligohydramnios
Skull defects
Most common side effect of oxybutynin
Dry mouth (antimuscarinic)
Absolute contraindications to COCP
<21 days post partum with other risk factors for VTE
0-6 weeks post partum and breastfeeding
Age >=35 and smokes >=15 cigarettes per day
Hypertension with BP >160 systolic or >100 diastolic
Vascular disease, heart disease, stroke/ TIA
History of VTE or current VTE
Major surgery (>30 mins) with prolonged immobilisation
Known thrombogenic mutation e.g. factor V Leiden
Antiphospholipid syndrome
Complicated valvular/ congenital heart disease (e.g. pulmonary hypertension)
Cardiomyopathy with impaired cardiac function
AF
Migraine with aura
Current breast cancer
Severe (decompensated) liver cirrhosis
MOA penicillins
Beta-lactam: inhibit peptidoglycan cross-links in bacterial cell wall synthesis (bactericidal)
MOA cephalosporins & examples
Beta lactam: inhibit peptidoglycan cross-links in bacterial cell wall synthesis (bactericidal)
Cefalexin, Ceftriaxone, Cefuroxime
MOA macrolides and examples
Excretion
Peptidyltransferase inhibitor. Reversibly bind 50S ribosome, block peptide elongation (bacteriostatic)
Erythromycin, Clarithromycin, Azithromycin
Excreted by liver
MOA fluoroquinolones and examples
DNA gyrase inhibitor- required to supercoil DNA = inhibit nucleic acid synthesis
Ciprofloxacin, Levofloxacin, Moxifloxacin, Ofloxacin
MOA Tetracyclines and examples
Bind to 30S subunit of microbial ribosomes, blocking attachment of aminoacyl-tRNA to the A site on the ribosome
Lymecycline, Oxytetracycline, Doxycycline
MOA Nitrofurantoin
Damages bacterial DNA via multiple reactive intermediaries
MOA Trimethoprim
Dihydrofolate reductase inhibitor (thus inhibiting bacterial DNA synthesis)
ACEi/ ARBs adverse effect on fetus/ neonate
Congenital Malformations
Renal dysgenesis
Oligohydramnios as a result of fetal oliguria
Pulmonary hypoplasia
IUGR
Neonatal anuric renal failure
Carbimazole adverse effect on fetus/ neonate
Choanal atresia
GIT defects
Omphalocoele
Aplasia cutis (missing section of skin)
Warfarin adverse effect on fetus/ neonate
Warfarin Embryopathy:
- Hypoplasia of nasal bridge
- Congenital heart defects
- Ventriculomegaly
- Agenesis of the corpus callosum
- Stippled epiphyses (focal bone calcification)
- Risk of intracranial haemorrhage in 3rd trimester
-Diaphragmatic hernia
Metronidazole adverse effect on fetus/ neonate
Diarrhoea
Lactose intolerance
Gentamicin/ Erythromycin adverse effect on fetus/ neonate
Ototoxicity
Tetracycline adverse effect on fetus/ neonate
Yellowing of teeth
Suggested link with cleft palate
Lithium adverse effect on fetus/ neonate
Cardiac Defects- Ebstein’s anomaly
Sodium Valporate adverse effect on fetus/ neonate
Cardiac Defects
SSRIs adverse effect on fetus/ neonate
Withdrawal syndrome in neonates
Some linked to CVS defects and Pulmonary Hypertension but evidence conflicting
Highest risk time to take warfarin?
6-12 weeks
5% chance of Warfarin emyropathy
Can Warfarin be used during breastfeeding?
Yes.
Women converted to LMWH during pregnancy should be changed back 5-7 days after delivery
Licensed use of Tamoxifen
Contraindications
MOA
Oestrogen receptor positive breast ca & anovulatory infertility
CI: personal or FHx of VTE
MOA: Selective Estrogen Receptor Modulator
(Increases risk of endometrial ca.)
Max dose of lidocaine
3mg/kg (without adrenaline)
7mg/kg (with adrenaline)
1% lidocaine = 1g/100ml or 10mg/ml.
Max dose for 70kg patient is 210mg = 21ml of 1% lidocaine
MOA of cyclizine
Histamine H1-receptor antagonist
MOA of Promethazine
Histamine H1-receptor antagonist
MOA Ondansetron
Serotonin 5-HT3 receptor antagonist
Prochlorperazine MOA
Dopamine D2 receptor antagonist